ArticleProceedings of the National Academy of Sciences of the United States of America2008
Modeling oncogene addiction using RNA interference.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 47 citations in OpenAlex.
- Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction.PloS one · 2021Article
- Effect of Cetuximab andYonago acta medica · 2019Article
- Autophosphorylation of the carboxyl-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants.International journal of cancer · 2018Article
- Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line.Pathology oncology research : POR · 2017Article
- Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.Oncotarget · 2015Article
- Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.Cancer research · 2013Article
- Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis.Cancer cell · 2013Article
- Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.PloS one · 2013Article
- Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.Cancer · 2012Article
- MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.Cancer research · 2012Article
- Emerging insights into the molecular and cellular basis of glioblastoma.Genes & development · 2012Review
- Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.BMC medicine · 2012Article
- Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo.Breast cancer research : BCR · 2012Article
- Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.Science translational medicine · 2011Article
- ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.Genes & cancer · 2011Article
- Oncogene addiction in gliomas: implications for molecular targeted therapy.Journal of experimental & clinical cancer research : CR · 2011Review
- EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.Nature medicine · 2011Article
- Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.Science translational medicine · 2011Article
- Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.Digestive diseases and sciences · 2010Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
The clinical efficacy of selective kinase inhibitors suggests that some cancer cells may become dependent on a single oncogene for survival. RNAi has been increasingly used to understand such "oncogene addiction" and validate new therapeutic targets. However, RNAi approaches suffer from significant off-target effects that limit their utility. Here, we combine carefully titrated lentiviral-mediated short hairpin RNA knockdown of the epidermal growth factor receptor (EGFR) with heterologous reconstitution by EGFR mutants to rigorously analyze the structural features and signaling activities that determine addiction to the mutationally activated EGFR in human lung cancer cells. EGFR dependence is differentially rescued by distinct EGFR variants and oncogenic mutants, is critically dependent on its heterodimerization partner ErbB-3, and surprisingly, does not require autophosphorylation sites in the cytoplasmic domain. Quantitative "oncogene rescue" analysis allows mechanistic dissection of oncogene addiction, and, when broadly applied, may provide functional validation for potential therapeutic targets identified through large-scale RNAi screens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.